Affinity Asset Advisors, LLC
13F Reported Value
ⓘ$1.9B
incl. option notional
Equity Holdings
ⓘ$1.7B
Option Notional
ⓘ$231.2M
$149.4M puts / $81.9M calls
Holdings
105
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Affinity Asset Advisors, LLC disclosed 105 positions worth $1.9B in its Form 13F-HR for Q1 2026 — $1.7B in common stock plus $231.2M of put/call option positions (reported at underlying notional value, not premium at risk), led by $SPY (SPDR S&P 500 ETF TRUST) puts, followed by $APGE and $XENE. During the quarter the fund opened 29 new positions and exited 18 — including a new stake in $SPY. The portfolio is most concentrated in Healthcare (99.1% of disclosed assets). All figures are sourced directly from Affinity Asset Advisors, LLC’s Form 13F-HR filing with the SEC under CIK 1773195.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$130.1M200,000 sh - —
Quality
$108.2M1,284,926 sh - 12.9#2,775
Quality
$97.4M1,675,000 sh - —
Quality
$86.6M5,350,000 sh - 29.4
Quality
$78.5M480,000 sh - —
Quality
$77.6M2,800,000 sh - —
Quality
$64.5M1,279,134 sh - —
Quality
$55.6M1,400,000 sh - $54.8M170,000 sh
- 29.4
Quality
$52.1M940,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 SPDR S&P 500 ETF TRUST$SPYPUT | — | $130.1M | 200,000 |
 Apogee Therapeutics, Inc.$APGE | — | $108.2M | 1,284,926 |
 Xenon Pharmaceuticals Inc.$XENE | 12.9#2,775 | $97.4M | 1,675,000 |
 Erasca, Inc.$ERAS | — | $86.6M | 5,350,000 |
 INSMED Inc$INSM | 29.4 | $78.5M | 480,000 |
 Roivant Sciences Ltd.$ROIV | — | $77.6M | 2,800,000 |
 Spyre Therapeutics, Inc.$SYRE | — | $64.5M | 1,279,134 |
 Centessa Pharmaceuticals plc$CNTA | — | $55.6M | 1,400,000 |
 Praxis Precision Medicines, Inc.$PRAX | — | $54.8M | 170,000 |
 ANAPTYSBIO, INC$ANAB | 29.4 | $52.1M | 940,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Affinity Asset Advisors, LLC's 105 positions.
Showing top 10 of 105 holdings.
Sector Allocation
Healthcare
$1.7B
Other
$12.7M
Financials
$2.7M
Full Holdings — Affinity Asset Advisors, LLC (Q1 2026)
All 105 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SPYPUT | SPDR S&P 500 ETF TRUST | $130.1M | — | NEW | — |
| 2 | $APGE | Apogee Therapeutics, Inc. | $108.2M | 6.3% | +4% | — |
| 3 | $XENE | Xenon Pharmaceuticals Inc. | $97.4M | 5.7% | +34% | 12.9 |
| 4 | $ERAS | Erasca, Inc. | $86.6M | 5.1% | +37% | — |
| 5 | $INSM | INSMED Inc | $78.5M | 4.6% | +7% | 29.4 |
| 6 | $ROIV | Roivant Sciences Ltd. | $77.6M | 4.5% | +65% | — |
| 7 | $SYRE | Spyre Therapeutics, Inc. | $64.5M | 3.8% | -11% | — |
| 8 | $CNTA | Centessa Pharmaceuticals plc | $55.6M | 3.3% | +133% | — |
| 9 | $PRAX | Praxis Precision Medicines, Inc. | $54.8M | 3.2% | -8% | — |
| 10 | $ANAB | ANAPTYSBIO, INC | $52.1M | 3.1% | +111% | 29.4 |
| 11 |  $ALKS | Alkermes plc. | $47.7M | 2.8% | +35% | — |
| 12 |  $CYTK | CYTOKINETICS INC | $46.2M | 2.7% | -12% | 28 |
| 13 |  $ABVX | Abivax S.A. | $45.1M | 2.6% | -20% | — |
| 14 |  $TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $42.2M | 2.5% | +0% | — |
| 15 |  $ACLX | Arcellx, Inc. | $41.7M | 2.4% | -31% | 6.7 |
| 16 |  $MRNACALL | Moderna, Inc. | $40.6M | — | NEW | 15.9 |
| 17 |  $NUVL | Nuvalent, Inc. | $30.7M | 1.8% | -7% | — |
| 18 |  $TERN | Terns Pharmaceuticals, Inc. | $29.7M | 1.7% | +2% | — |
| 19 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $29.4M | 1.7% | +204% | 26.8 |
| 20 |  $LXEO | Lexeo Therapeutics, Inc. | $29.0M | 1.7% | +58% | — |
| 21 |  $COGT | Cogent Biosciences, Inc. | $28.9M | 1.7% | +114% | — |
| 22 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $28.8M | 1.7% | +77% | 25.4 |
| 23 |  $STRO | SUTRO BIOPHARMA, INC. | $26.6M | 1.6% | +43% | 30.1 |
| 24 |  $FBRX | Forte Biosciences, Inc. | $26.2M | 1.5% | +2% | — |
| 25 |  $ORKA | Oruka Therapeutics, Inc. | $24.5M | 1.4% | -38% | — |
| 26 |  $TRVI | Trevi Therapeutics, Inc. | $23.9M | 1.4% | -7% | — |
| 27 |  $OVID | Ovid Therapeutics Inc. | $23.6M | 1.4% | +49% | 13.1 |
| 28 |  $ELVN | Enliven Therapeutics, Inc. | $23.0M | 1.4% | NEW | — |
| 29 |  $ASND | Ascendis Pharma A/S | $21.7M | 1.3% | +217% | 41.5 |
| 30 |  $MLYS | Mineralys Therapeutics, Inc. | $20.3M | 1.2% | +3% | — |
| 31 |  $AVTX | Avalo Therapeutics, Inc. | $20.0M | 1.2% | +28% | 4.6 |
| 32 |  $BMYCALL | BRISTOL MYERS SQUIBB CO | $18.2M | — | NEW | 70.1 |
| 33 |  $PTGX | Protagonist Therapeutics, Inc | $18.1M | 1.1% | +0% | 24.8 |
| 34 |  $CLDX | Celldex Therapeutics, Inc. | $15.9M | 0.9% | +43% | 13.2 |
| 35 |  $ZURA | Zura Bio Ltd | $15.3M | 0.9% | +41% | — |
| 36 |  $NRIX | Nurix Therapeutics, Inc. | $15.0M | 0.9% | +0% | 13.2 |
| 37 |  $SVRA | Savara Inc | $13.7M | 0.8% | -10% | — |
| 38 |  $OMER | OMEROS CORP | $13.2M | 0.8% | +0% | — |
| 39 |  $CATX | Perspective Therapeutics, Inc. | $13.2M | 0.8% | +955% | — |
| 40 | — | HELIX ACQUISITION CORP III | $12.7M | 0.7% | NEW | — |
| 41 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $12.5M | 0.7% | +186% | 74.4 |
| 42 |  $DMRA | Damora Therapeutics, Inc. | $11.7M | 0.7% | NEW | — |
| 43 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $11.5M | 0.7% | +430% | — |
| 44 |  $ANRO | Alto Neuroscience, Inc. | $11.2M | 0.7% | NEW | — |
| 45 |  $BBIO | BridgeBio Pharma, Inc. | $11.1M | 0.7% | -53% | 31.7 |
| 46 |  $CGEM | Cullinan Therapeutics, Inc. | $11.1M | 0.7% | -60% | — |
| 47 |  $BLTE | BELITE BIO, INC | $10.4M | 0.6% | +225% | — |
| 48 |  $WVE | Wave Life Sciences Ltd. | $10.2M | 0.6% | -48% | — |
| 49 |  $VERA | Vera Therapeutics, Inc. | $10.1M | 0.6% | +0% | — |
| 50 |  $TYRA | Tyra Biosciences, Inc. | $9.9M | 0.6% | NEW | — |
| 51 |  $RVMDPUT | Revolution Medicines, Inc. | $9.7M | — | NEW | — |
| 52 | $RVMD | Revolution Medicines, Inc. | $9.7M | 0.6% | +0% | — |
| 53 |  $IBRXPUT | ImmunityBio, Inc. | $9.6M | — | NEW | 30 |
| 54 |  $JBIO | Jade Biosciences, Inc. | $9.0M | 0.5% | -10% | — |
| 55 |  $TVTX | Travere Therapeutics, Inc. | $8.9M | 0.5% | +0% | 39.2 |
| 56 |  $NAMS | NewAmsterdam Pharma Co N.V. | $8.8M | 0.5% | +0% | — |
| 57 | $COGT | Cogent Biosciences, Inc. | $8.6M | 0.5% | +600% | — |
| 58 |  $KRRO | Korro Bio, Inc. | $8.0M | 0.5% | NEW | 5.8 |
| 59 |  $CELC | Celcuity Inc. | $7.3M | 0.4% | +0% | — |
| 60 |  $CRSP | CRISPR Therapeutics AG | $7.1M | 0.4% | NEW | 4.5 |
| 61 |  $SGP | SpyGlass Pharma, Inc. | $6.5M | 0.4% | NEW | — |
| 62 |  $NVOCALL | NOVO NORDISK A S | $6.4M | — | NEW | — |
| 63 |  $CMPS | COMPASS Pathways plc | $6.1M | 0.4% | +454% | — |
| 64 |  $IBIO | iBio, Inc. | $5.9M | 0.3% | +51% | — |
| 65 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $5.7M | 0.3% | -50% | 26.7 |
| 66 |  $AVR | Anteris Technologies Global Corp. | $5.1M | 0.3% | +87% | — |
| 67 | $NAMS | NewAmsterdam Pharma Co N.V. | $4.9M | 0.3% | +0% | — |
| 68 |  $QURECALL | uniQure N.V. | $4.9M | — | -63% | — |
| 69 |  $VRDN | Viridian Therapeutics, Inc.\DE | $4.9M | 0.3% | +0% | 30.5 |
| 70 |  $CLYM | Climb Bio, Inc. | $4.8M | 0.3% | -46% | — |
| 71 |  $RZLT | Rezolute, Inc. | $4.7M | 0.3% | -34% | — |
| 72 |  $SGMT | Sagimet Biosciences Inc. | $4.5M | 0.3% | -24% | — |
| 73 |  $MBX | MBX Biosciences, Inc. | $4.5M | 0.3% | -40% | — |
| 74 |  $TSHA | Taysha Gene Therapies, Inc. | $4.5M | 0.3% | -70% | 4.1 |
| 75 |  $MANE | Veradermics, Inc | $4.4M | 0.3% | NEW | — |
| 76 |  $GENB | Generate Biomedicines, Inc. | $4.4M | 0.3% | NEW | — |
| 77 | $DNTHCALL | Dianthus Therapeutics, Inc. /DE/ | $4.2M | — | NEW | 26.8 |
| 78 |  $ENGN | enGene Therapeutics Inc. | $4.2M | 0.2% | -5% | — |
| 79 |  $CGONCALL | CG Oncology, Inc. | $4.1M | — | NEW | 28 |
| 80 |  $AVBP | ArriVent BioPharma, Inc. | $4.0M | 0.2% | +17% | — |
| 81 |  $RLAY | Relay Therapeutics, Inc. | $4.0M | 0.2% | NEW | 12.7 |
| 82 |  $PRQR | ProQR Therapeutics N.V. | $4.0M | 0.2% | +0% | — |
| 83 |  $VRCA | Verrica Pharmaceuticals Inc. | $3.7M | 0.2% | +0% | 26.1 |
| 84 | $CELCCALL | Celcuity Inc. | $3.4M | — | NEW | — |
| 85 |  $DTIL | PRECISION BIOSCIENCES INC | $3.3M | 0.2% | NEW | 3.9 |
| 86 |  $KPTI | Karyopharm Therapeutics Inc. | $2.8M | 0.2% | -44% | 20.4 |
| 87 |  $SLGL | Sol-Gel Technologies Ltd. | $2.8M | 0.2% | NEW | — |
| 88 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $2.7M | 0.2% | +0% | 26.5 |
| 89 |  $OACC | Oaktree Acquisition Corp. III Life Sciences | $2.7M | 0.2% | +0% | — |
| 90 |  $NXTC | NextCure, Inc. | $2.6M | 0.1% | -2% | — |
| 91 |  $IMVT | Immunovant, Inc. | $2.5M | 0.1% | -50% | — |
| 92 |  $EQ | Equillium, Inc. | $2.5M | 0.1% | NEW | 27.2 |
| 93 |  $SABS | SAB Biotherapeutics, Inc. | $2.2M | 0.1% | NEW | — |
| 94 |  $CORT | CORCEPT THERAPEUTICS INC | $2.0M | 0.1% | NEW | 55.4 |
| 95 |  $OBIO | Orchestra BioMed Holdings, Inc. | $1.7M | 0.1% | -30% | 8.7 |
| 96 |  $KZR | Kezar Life Sciences, Inc. | $1.7M | 0.1% | +0% | — |
| 97 |  $MGNX | MACROGENICS INC | $1.4M | 0.1% | +3% | 31.7 |
| 98 |  $ANL | Adlai Nortye Ltd. | $1.1M | 0.1% | NEW | — |
| 99 |  $ALEC | Alector, Inc. | $1.1M | 0.1% | NEW | 8.9 |
| 100 |  $OKUR | OnKure Therapeutics, Inc. | $997,587 | 0.1% | NEW | — |
| 101 |  $LENZ | LENZ Therapeutics, Inc. | $915,000 | 0.1% | NEW | 19.6 |
| 102 |  $XFOR | X4 Pharmaceuticals, Inc | $598,850 | 0.0% | +0% | 29.3 |
| 103 |  $QTTB | Q32 Bio Inc. | $178,328 | 0.0% | +0% | 23.1 |
| 104 |  $ADGM | Adagio Medical Holdings, Inc. | $92,000 | 0.0% | +0% | — |
| 105 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $1,178 | 0.0% | +0% | — |
New Positions (29)
$SPYPUT SPDR S&P 500 ETF TRUST$130.1M$MRNACALL Moderna, Inc.$40.6M$ELVN Enliven Therapeutics, Inc.$23.0M$BMYCALL BRISTOL MYERS SQUIBB CO$18.2M$DMRA Damora Therapeutics, Inc.$11.7M$ANRO Alto Neuroscience, Inc.$11.2M$TYRA Tyra Biosciences, Inc.$9.9M$RVMDPUT Revolution Medicines, Inc.$9.7M$IBRXPUT ImmunityBio, Inc.$9.6M$KRRO Korro Bio, Inc.$8.0M$CRSP CRISPR Therapeutics AG$7.1M$SGP SpyGlass Pharma, Inc.$6.5M$NVOCALL NOVO NORDISK A S$6.4M$MANE Veradermics, Inc$4.4MExited Positions (18)
$VTYX Ventyx Biosciences, Inc.
$AMGNCALL AMGEN INC
$TNGX Tango Therapeutics, Inc.
$RCUS Arcus Biosciences, Inc.
$SMMTPUT Summit Therapeutics Inc.
$AVDL AVADEL PHARMACEUTICALS PLC$AMGN AMGEN INC
$ABUSCALL Arbutus Biopharma Corp
$GERN GERON CORP
$RARE Ultragenyx Pharmaceutical Inc.$LENZPUT LENZ Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Affinity Asset Advisors, LLC including:
Track Affinity Asset Advisors, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Affinity Asset Advisors, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Affinity Asset Advisors, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Affinity Asset Advisors, LLC (SEC CIK: 1773195), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Affinity Asset Advisors, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.